Surfactant: A review of its functions and relevance in adult respiratory disorders

Respiratory Medicine

Volumn 90, Issue 5, 1996, Pages 251-270

  Hamm, H ^a   Kroegel, C ^a   Hohlfeld, J ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LUNG SURFACTANT; PHOSPHOLIPID; PROTEIN A; PROTEIN C; SURFACTANT;

ADULT RESPIRATORY DISTRESS SYNDROME; LUNG ALVEOLUS CELL TYPE 2; LUNG ALVEOLUS MACROPHAGE; LUNG FUNCTION; PNEUMONIA; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0029941635     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(96)90097-9     Document Type: Review

References (204)

1. von Neergard K. Neue Auffassungen über einen Grundbegriff der Atemmechanik. Z Ges Exp Med 1929; 66: 373-383.
2. Pattle RE. Properties, function and origin of the alveolar lining layer. Nature 1955; 175: 1125-1126.
3. Clements JA. Surface tension of lung extracts. Proc Soc Exp Biol Med 1957; 95: 170-172.
4. Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 1959; 97: 517-523.
5. Horbar JD, Wright EC, Onstad L. Decreasing mortality associated with the introduction of surfactant therapy: an observational study of neonates weighing 601 to 1300 grams at birth. Pediatrics 1993; 92: 191-196.
6. Jobe A, Ikegami M. Surfactant for the treatment of respiratory distress syndrome. Am Rev Respir Dis 1987; 136: 1256-1275.
7. 2. Respiration 1983; 44: 63-70.
8. Harwood JL. Lung surfactant. Prog Lipid Res 1987; 26: 211-256.
9. Hamm H, Bartsch W, Fabel H. The surfactant system of the adult lung: physiology and clinical perspectives. Clin Invest 1992; 70: 637-657.
10. Barrow RE, Hills BA. Surface tension induced by dipalmitoyl lecithin in vitro under physiological conditions. J Physiol 1979; 297: 217-227.
11. Batenburg JJ. Surfactant phospholipids: synthesis and storage. Am J Physiol 1992; 262: L367-L385.
12. Wright JR, Clements JA. Metabolism and turnover of lung surfactant. Am Rev Respir Dis 1987; 135: 426-444.
13. Possmayer F. A proposed nomenclature for pulmonary surfactant-associated proteins. Am Rev Respir Dis 1988; 138: 990-998.
14. Persson A, Chang D, Rust K, Moxley M, Longmore W, Crouch E. Purification and biochemical characterization of CP4 (SP-D), a collagenous surfactant-associated protein. Biochemistry 1989; 28: 6361-6367.
15. Hawgood S. Pulmonary surfactant apoproteins: a review of protein and genomic structure. Am J Physiol 1989; 257: L13-L22.
16. Johansson J, Curstedt T, Robertson B. The proteins of the surfactant system. Eur Respir J 1994; 7: 372-391.
17. Coulombe PA, Bendayan M. Lung surfactant associated proteins and type IV collagen share common epitopes. Am Rev Respir Dis 1989; 140: 1040-1044.
18. Voss T, Eistetter H, Schäfer KP, Engel J. Macromolecular organization of natural and recombinant lung surfactant protein SP 28-36. J Mol Biol 1988; 201: 219-227.
19. Voorhout WF, Veenendaal T, Haagsman HP, Verkleij AJ, van Golde LMG, Geuze HJ. Surfactant protein A is localized at the corners of the pulmonary tubular myelin lattice. J Histochem Cytochem 1991; 39: 1331-1336.
20. Williams MC, Hawgood S, Hamilton RL. Changes in lipid structure produced by surfactant proteins SP-A, SP-B and SP-C. Am J Respir Cell Mol Biol 1991; 5: 41-50.
21. Williams MC, Morphologic aspects of the surfactant system. In: Robertson B, van Golde LMG, Batenburg JJ, eds. Pulmonary Surfactant. From Molecular Biology to Clinical Practice. Amsterdam: Elsevier, 1992, pp. 87-107.
22. Floros J. Sixty years of surfactant research. Am J Physiol (Lung Cell Mol Physiol) 1990; 2: L238-L240.
23. Possmayer F. The role of surfactant-associated proteins. Am Rev Respir Dis 1990; 142: 749-752.
24. Hawgood S. The hydrophilic surfactant protein SP-A: Molecular biology, structure and function. In: Robertson B, van Golde LMG, Batenburg JJ, eds. Pulmonary Surfactant. Amsterdam: Elsevier, 1992, pp. 33-54.
25. Tenner AJ, Robinson SL, Borchelt J, Wright JR. Human pulmonary surfactant protein (SP-A), a protein structurally homologous to C1q, can enhance FcR- and CR1-mediated phagocytosis. J Biol Chem 1989; 264: 13923-13928.
26. van Iwaarden F, Welmers B, Verhoef J, Haagsman HP, van Golde LMG. Pulmonary surfactant protein A enhances the host-defense mechanism of rat alveolar macrophages. Am J Respir Cell Mol Biol 1990; 2: 91-98.
27. Manz-Keinke H, Plattner H, Schlepper-Schäfer J. Lung surfactant protein A (SP-A) enhances serum-independent phagocytosis of bacteria by alveolar macrophages. Eur J Cell Biol 1992; 57: 95-100.
28. van Iwaarden JF, van Strijp JA, Ebskamp MJ, Welmers AC, Verhoef J, van Golde LMG. Surfactant protein A is opsonin in phagocytosis of herpes simplex virus type 1 by rat alveolar macrophages. Am J Physiol 1991; 261: L204-L209.
29. Benne CA, Kraaijeveld CA, van Strijp JA et al. Interactions of pulmonary surfactant protein A (SP-A) with influenza A viruses: binding and neutralization. J Infect Dis 1995; 171: 335-341.
30. van Iwaarden JF, van Strijp JAG, Visser H, Haagsman HP, Verhoef J, van Golde LMG. Binding of surfactant protein A (SP-A) to herpes simplex virus type-1 infected cells is mediated by the carbohydrate moiety of SP-A. J Biol Chem 1992; 267: 25039-25043.
31. Zimmerman PE, Voelker DR, McCormack FX, Paulsrud JR, Martin WJ. 120-kD surface glycoprotein of P. carinii is a ligand for surfactant protein A. J Clin Invest 1992; 89: 143-149.
32. Phelps DS.The role of surfactant in the pathogenesis of pneumonia. In: Müller B, v. Wichert P, eds. Lung Surfactant: Basic Research in the Pathogenesis of Lung Disorders. Basel: Karger, 1994: 216-221.
33. Downing JF, Pasula R, Wright JR, Twigg HL, Martin WJ. Surfactant protein A promotes attachment of Mycobacterium tuberculosis to alveolar macrophages during infection with human immunodeficiency virus. Proc Natl Acad Sci 1995; 92: 4848-4852.
34. Dobbs LG, Wright JR, Hawgood S, Gonzalez R, Venstrom K, Nellenbogen J. Pulmonary surfactant and its components inhibit secretion of phosphatidylcholine from cultured rat alveolar type II cells. Proc Natl Acad Sci USA 1987; 84: 1010-1014.
35. Wright JR, Wager RE, Hawgood S, Dobbs LG, Clements JA. Surfactant apoprotein Mr=26.000-36.000 enhances uptake of liposomes by type II cells. J Biol Chem 1987; 262: 2888-2894.
36. Strayer DS, Yang S, Jerng HH. Surfactant protein A-binding proteins. J Biol Chem 1993; 268: 18679-18684.
37. Weaver TE, Sarin VK, Sawtell N, Hull WM, Whitsett JA. Identification of surfactant proteolipid SP-B in human surfactant and fetal lung. J Apply Physiol 1988; 65: 982-987.
38. Whitsett JA, Baatz JE. Hydrophobic surfactant proteins SP-B and SP-C: molecular biology, structure and function. In: Robertson B, van Golde LMG, Batenburg JJ, eds. Pulmonary Surfactant. From Molecular Biology to Clinical Practice. Amsterdam: Elsevier, 1992: 55-75.
39. Johannson J, Curstedt T, Jörnvall H. Surfactant protein B: Disulfide bridges, structural properties and kringle similarities. Biochem 1991; 30: 6917-6921.
40. Weaver TE, Whitsett JA. Function and regulation of expression of pulmonary surfactant-associated proteins. Biochem J 1991; 273: 249-264.
41. Baatz JE, Elledge B, Whitsett JA. Surfactant protein SP-B induces ordering at the surface of model membrane bilayers. Biochemistry 1990; 29: 6714-6720.
42. Takahashi A, Waring AJ, Amirkhanian J, Fan B, Taeusch HW. Structure-function relationships of bovine pulmonary surfactant proteins SP-B and SP-C. Biochim Biophys Acta 1990; 1044: 43-49.
43. Cochrane CG, Revak SD. Pulmonary surfactant protein B (SP-B): structure-function relationships. Science 1991; 254: 566-568.
44. Nogee LM, DeMello DE, Dehner LP, Colten HR. Brief report: deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. N Engl J Med 1993; 328: 406-410.
45. Seeger W, Thede C, Günther A, Grube C. Surface properties and sensitivity to protein-inhibition of a recombinant apoprotein C-based phospholipid mixture in vitro: comparison to natural surfactant. Biochim Biophys Acta 1991; 1081: 45-52.
46. Yu SH, Possmayer F. Role of bovine pulmonary surfactant-associated proteins in the surface-active property of phospholipid mixtures. Biochim Biophys Acta 1990; 1046: 233-242.
47. Persson A, Chang D, Crouch E. Surfactant protein D is a divalent cation-dependent carbohydrate-binding protein. J Biol Chem 1990; 265: 5755-5760.
48. Voorhout WF, Veenendaal T, Kuroki Y, Ogasawara Y, van Golde LMG, Geuze HJ. Immunocytochemical localization of surfactant protein D (SP-D) in type II cells, Clara cells, and alveolar macrophages of rat lung. J Histochem Cytochem 1992; 40: 1589-1597.
49. Crouch E, Parghi D, Kuan SF, Persson A. Surfactant protein D: Subcellular localization in nonciliated bronchiolar epithelial cells. Am J Physiol 1992; 263: L60-L66.
50. Kuroki Y, Shiratori M, Ogaswara Y, Tsuzuki A, Akino T. Characterization of pulmonary surfactant protein D: its copurification with lipids. Biochim Biophys Acta 1991; 1086: 185-190.
51. Weaver TE. Surfactant proteins and SP-D. Am J Respir Cell Mol Biol 1991; 5: 4-5.
52. Crouch E, Kuan SF, Persson A. Surfactant protein D: possible roles in pulmonary host defense. In: Müller B, von Wiehert P, eds. Lung Surfactant: Baasic Research in the Pathogenesis of Lung Disorders. Basel: Karger, 1994, pp. 132-140.
53. Kuan SF, Rust K, Crouch E. Interactions of surfactant protein D with bacterial lipopolysaccharides. Surfactant protein D is an Escherichia coli-binding protein in bronchoalveolar lavage. J Clin Invest 1992; 90: 97-106.
54. van Iwaarden JF, Shimizu H, van Golde PHM, Voelker DR, van Golde LMG. Rat surfactant protein D enhances the production of oxygen radicals by rat alveolar macrophages. Biochem J 1992; 286: 5-8.
55. Kuroki Y, Shiratori M, Murata Y, Akino T. Surfactant protein D (SP-D) counteracts the inhibitory effect of surfactant protein A (SP-A) on phospholipid secretion by alveolar type II cells. Biochem J 1991; 279: 115-119.
56. Crapo JD, Barry BE, Gehr P, Bachofen J, Weibel ER. Cell number and cell characteristics of the normal human lung. Am Rev Respir Dis 1982; 126: 332-337.
57. Auten RL, Watkins RH, Shapiro DL, Horowitz S. Surfactant apoprotein A (SP-A) is synthesized in airway cells. Am J Respir Cell Mol Biol 1990; 3: 491-496.
58. Ten Have-Opbroek AAW, Otto-Verberne CJM, Dubbeldam JA, Dykman JH. The proximal border of the human respiratory unit, as shown by scanning and transmission electron microscopy and light microscopical cytochemistry. Anat Rec 1991; 229: 339-354.
59. Barrow RE. Chemical structure of phospholipids in the lungs and airways of sheep. Respir Physiol 1990; 79: 1-8.
60. Yamanaka N, Kobayashi K, Kataura A, Kuroki Y, Akino T. Implication of surfactant apoprotein in otitis media with effusion. Ann Otol Rhinol Laryngol 1991; 100: 835-840.
61. Dobbs LG. Pulmonary surfactant. Ann Rev Med 1989; 40: 431-436.
62. van Golde LMG, Batenburg JJ, Robertson B. Metabolism of phospholipids in the lung. Physiol Rev 1988; 68: 374-455.
63. Ballard PL. Hormonal regulation of pulmonary surfactant. Endocr Rev 1989; 10: 165-181.
64. Chander A, Fisher AB. Regulation of lung surfactant secretion. Am J Physiol (Lung Cell Mol Physiol 2) 1990; 258: L241-L253.
65. Wright JR. Clearance and recycling of pulmonary surfactant. Am J Physiol 1990; 259: L1-L12.
66. Haagsman HP, van Golde LMG. Synthesis and assembly of lung surfactant. Annu Rev Physiol 1991; 53: 441-464.
67. Wright JR, Youmans DC, Pison U. Metabolism and degradation of alveolar surfactant. In: Müller B, v. Wiehert P, eds. Lung Surfactant: Basic Research in the Pathogenesis of Lung Disorders. Basel: Karger, 1994, pp. 69-73.
68. Fisher AB, Dodia C. Regulation of surfactant metabolism: degradation of internalized alveolar phosphatidylcholine. In: Müller B, v. Wiehert P, eds. Lung Surfactant: Basic Research in the Pathogenesis of Lung Disorders. Basel: Karger, 1994, pp. 74-83.
69. Phelphs DS, Floros J. Localization of surfactant protein synthesis in human lung by in situ hybridization. Am Rev Respir Dis 1988; 137: 939-942.
70. Liley HG, White RT, Benson BJ, Ballard PL. Glucocorticoids both stimulate and inhibit production of pulmonary surfactant protein A in fetal human lung. Proc Natl Acad Sci USA 1988; 85: 9096-9100.
71. Fisher JH, McCormack F, Park SS, Stelzner T, Shannon JM, Hofmann T. In vivo regulation of surfactant proteins by glucocorticoids. Am J Respir Cell Mol Biol 1991; 5: 63-70.
72. Ianuzzi DM, Ertsey R, Ballard PL. Biphasic glucocorticoid regulation of pulmonary SP-A: characterization of inhibitory process. Am J Physiol 1993; 264: L236-L244.
73. Doyle IR, Barr HA, Nicholas TE. Distribution of surfactant protein A in rat lung. Am J Respir Cell Mol Biol 1994; 11: 405-415.
74. Wirtz H, Schmidt M. Ventilation and secretion of pulmonary surfactant. Clin J Investig 1992; 70: 3-13.
75. Hallman M, Epstein BL, Gluck L. Analysis of labeling and clearance of lung surfactant phospholipids in rabbit. J Clin Invest 1981; 68: 742-751.
76. Rooney SA. The surfactant system of the lung. In: Witschi HP, Brain JD, eds. Toxicology of Inhaled Particles, 1985, pp. 471-502.
77. Miles PR, Ma JYC, Bowman L. Degredation of pulmonary surfactant disaturated phosphatidylcholines by alveolar macrophages. J Appl Physiol 1988; 64: 2474-2481.
78. Manz-Keinke H, Egenhofer C, Plattner H, Schlepper-Schäfer J. Specific interaction of lung surfactant protein A (SP-A) with rat alveolar macrophages. Exp Cell Res 1991; 192: 597-603.
79. Pettenazzo A, Jobe A, Humme J, Seidner S, Ikegami M. Clearance of surfactant phosphatidylcholine via the upper airways in rabbits. J Appl Physiol 1988; 65: 2151-2155.
80. Pettenazzo A, Ikegami M, Seidner S, Jobe A. Clearance of surfactant phosphatidylcholine from adult rabbit lungs. J Appl Physiol 1988; 64: 120-127.
81. Goerke J. Surfactant and lung mechanics. In: Robertson B, van Golde LMG, Batenburg JJ, eds. Pulmonary Surfactant. From Molecular Biology to Clinical Practice. Amsterdam: Elsevier, 1992, pp. 165-192.
82. Matalon S, Holm BA, Baker RR, Whitfield MK, Freeman BA. Characterization of antioxidant activities of pulmonary surfactant mixtures. Biochim Biophys Acta 1990; 1035: 121-127.
83. Coonrod JD. Role of surfactant free fatty acids in antimicrobial defenses. Eur J Respir Dis 1987; 71: 209-214.
84. Jonsson S, Musher DM, Goree A, Lawrence EC. Human alveolar lining material and antibacterial defenses. Am Rev Respir Dis 1986; 133: 136-140.
85. Catanzaro A, Richman P, Batcher S, Hallman M. Immunomodulation by pulmonary surfactant. J Lab Clin Med 1988; 112: 727-734.
86. Wilsher ML, Hughes DA, Haslam PL. Immunoregulatory properties of pulmonary surfactant: effect of lung lining fluid on proliferation of human blood lymphocytes. Thorax 1988; 43: 354-359.
87. Sitrin RG, Ansfield MJ, Kaltreider HB. The effect of pulmonary surface-active material on the generation and expression of murine B- and T-lymphocyte effector functions in vitro. Exp Lung Res 1985; 9: 85-97.
88. Wilsher ML, Parker DJ, Haslam PL. Immunosupression by pulmonary surfactant: mechanisms of action. Thorax 1990; 45: 3-8.
89. Baughman RP, Strohofer S. Lung derived surface active material (SAM) inhibits natural killer cell tumor cytotoxicity. J Clin Lab Immunol 1989; 28: 51-54.
90. O'Neill S, Lesperance E, Klass DJ. Rat lung lavage surfactant enhances bacterial phagocytosis and intracellular killing by alveolar macrophages. Am Rev Respir Dis 1984; 130: 225-230.
91. Juers JA, Rogers RM, McCurdy JB, Cook WW. Enhancement of bactericidal capacity of alveolar macrophages by human alveolar lining material. J Clin Invest 1976; 58: 271-275.
92. Schwartz LW, Christman CA. Alveolar macrophage migration - Influence of lung lining material. Am Rev Respir Dis 1979; 120: 429-439.
93. Baughman RP, Mangels DJ, Strohofer S, Corser BC. Enhancement of macrophage and monocyte cytotoxicity by the surface active material of lung lining fluid. J Lab Clin Med 1987; 109: 692-697.
94. Allen JN, Moore SA, Popeharman AL, Marsh CB, Wewers MD. Immunosupressive properties of surfactant and plasma on alveolar macrophages. J Lab Clin Med 1995; 125: 356-369.
95. Guzman J, Izumi T, Nagai S, Costabel U. ICAM-1 and integrin expression on isolated human alveolar type II pneumocytes. Eur Respir J 1994; 7: 736-739.
96. Kroegel C, Luttmann W. Virchow Jr JC, Matthys H, Hasse H, Freudenberg N. Alveolar type I and alveolar type II pneumocytes express ICAM-1 in human lung tissue, (submitted).
97. Schneeberger FE, DeFerrari M, Skoskiewicz J, Russel PS, Colvin RB. Introduction of MHC determined antigens in the lung by interferon-γ. Lab Invest 1986; 55: 138-144.
98. Harbeck RJ, Gegen NW, Struhar D, Mason R. Class II molecules on rat alveolar type II epithelial cells. Cell Immunol 1988; 111: 139-147.
99. Damjanovich L, Albedla SM, Mette SA, Buck CA. Distribution of integrin cell adhesion receptors in normal and malignant lung tissue. Am J Respir Cell Mol Biol 1992; 6: 197-206.
100. Montefort, Baker J, Roche WR, Holgate ST. The distribution of adhesive mechanisms in normal bronchial epithelium. Eur Respir J 1993; 6: 1257-1263.
101. Khalil N, O'Connor RN, Unruh HW et al. Increased production and immunohistochemical localization of transforming growth factor-β in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 1991; 5: 155-162.
102. Nash JRG, McLaughlin PJ, Butcher D, Corrin B. Expression of tumor necrosis factor-alpha in cryptogenic fibrosing alveolitis. Histopathology 1993; 22: 343-347.
103. Raaberg L, Nexo E, Buckley S, Luo W, Snead ML, Warburton D. Epidermal growth factor transcription, translation, and signal transduction by rat type II pneumocytes in culture. Am J Respir Cell Mol Biol 1992; 6: 44-49.
104. Punjabi CJ, Laskin JD, Pendino KJ, Goller NL, Durham SK, Laskin DL. Production of nitric oxide by rat type II pneumocytes: increased expression of inducible nitric oxide synthetase following inhalation of a pulmonary irritant. Am J Respir Cell Mol Biol 1994; 11: 165-172.
105. Ariasdiaz J, Vara E, Garcia C, Balbrea JL. Tumor necrosis factor-alpha-induced inhibition of phosphatidylcholine synthesis by human type II pneumocytes is partially inhibited by prostaglandins. J Clin Invest 1994; 94: 244-250.
106. Cott GR, Westcott JY, Voelkel NF. Prostaglandin and leukotriene production by alveolar type II cells in vitro. Am J Physiol 1990; 258: L179-L187.
107. Maghni K, Robidoux C, Laporte J, Hailee A, Sirois P. Release of prostaglandins and thromboxanes by guinea pig isolated type II pneumocytes. Prostaglandins 1990; 40: 217-227.
108. Grimmiger F, von Kürten I, Walmrath D, Seeger W. Type II alveolar epithelial eicosanoid metabolism: prominence of cyclooxygenase pathways and transcellular lipoxygenase metabolism in co-culture with neutrophils. Am J Respir Cell Mol Biol 1992; 6: 9-16.
109. Luttmann W, Herzog V, Virchow Jr JC, Matthys H, Thierauch KH, Kroegel C. Prostacyclin modulates granulocyte macrophage colony-stimulating factor by human blood mononuclear cells. Clin Immunol Immunopathol 1995 (in press).
110. Paine R, Mody CH, Chavis A, Spahr MA, Turka LA, Toews GB. Alveolar epithelial cells block lymphocyte proliferation in vitro without inhibiting activation. Am J Respir Cell Mol Biol 1991; 5: 221-229.
111. Marcy TW, Merrill WW, Rankin JA, Reynolds HY. Limitations of using urea to quantify epithelial lining fluid recovered by bronchoalveolar lavage. Am Rev Respir Dis 1987; 135: 1276-1280.
112. Kelly CA, Fenwick JD, Corris PA, Fleetwood A, Hendrick DJ, Walters EH. Fluid dynamics during bronchoalveolar lavage. Am Rev Respir Dis 1988; 138: 81-84.
113. von Wiehert P. Joseph K, Müller B, Franck WM. Bronchoalveolar lavage - quantitation of intraalveolar fluid? Am Rev Respir Dis 1993; 147: 148-152.
114. Doyle IR, Jones ME, Barr HA et al. Composition of human pulmonary surfactant varies with exercise and level of fitness. Am J Respir Crit Care Med 1994; 149: 1619-1627.
115. Hallman M, Maasilta P, Kivisaari L, Mattson K. Changes in surfactant in bronchoalveolar lavage fluid after hemithorax irradiation in patients with mesothelioma. Am Rev Respir Dis 1990; 141: 998-1005.
116. McCormack FX, King TE, Voelker DR, Robinson PC, Mason RJ. Idiopathic pulmonary fibrosis. Abnormalities in the bronchoalveolar lavage content of surfactant protein A. Am Rev Respir Dis 1991; 144: 160-166.
117. Phelps DS, Rose RM. Increased recovery of surfactant protein A in AIDS-related pneumonia. Am Rev Respir Dis 1991; 143: 1072-1075.
118. van de Graaf EA, Jansen HM, Lutter R et al. Surfactant protein A in bronchoalveolar lavage fluid. J Lab Clin Med 1992; 120: 252-263.
119. Hamm H, Lührs J, Guzman y Rotache J, Costabel U, Fabel H, Bartsch W. Elevated surfactant protein A in bronchoalveolar lavage fluids from sarcoidosis and hypersensitivity pneumonitis patients. Chest 1994; 106: 1766-1770.
120. Baughman RP, Sternberg RI, Hull W, Buchsbaum JA, Whitsett J. Decreased surfactant protein A in patients with bacterial pneumonia. Am Rev Respir Dis 1993; 147: 653-657.
121. Inoue T, Matsuura E, Nagata A et al. Enzyme-linked immunosorbent assay for human pulmonary surfactant protein D. J Immunol Methods 1994; 173: 157-164.
122. Hallman M, Spragg R, Harrell JH, Moser KM, Gluck L. Evidence of lung surfactant abnormality in respiratory failure. J Clin Invest 1982; 70: 673-683.
123. Pison U, Seeger W, Buchhorn R et al. Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am Rev Respir Dis 1989; 140: 1033-1039.
124. Honda Y, Kataoka K, Hayashi H, Takahashi H, Suzuki A, Akino T. Alterations of acidic phospholipids in bronchoalveolar lavage fluids of patients with pulmonary alveolar proteinosis. Clin Chim Acta 1989; 181: 11-18.
125. Hughes DA, Haslam PL. Changes in phosphatidylglycerol in bronchoalveolar lavage fluids from patients with cryptogenic fibrosing alveolitis. Chest 1989; 95: 82-89.
126. Honda Y, Tsunematsu K, Suzuki A, Akino T. Changes in phospholipids in bronchoalveolar lavage fluid of patients with interstitial lung diseases. Lung 1988; 166: 293-301.
127. Robinson PC, Watters LC, King TE, Mason RJ. Idiopathic pulmonary fibrosis-abnormalities in bronchoalveolar lavage fluid. Am Rev Respir Dis 1988; 137: 585-591.
128. Bernhard W, Linck M, Creutzburg H et al. High-performance liquid chromatographic analysis of phospholipids from different sources with combined flourescence and ultraviolet detection. Anal Biochem 1994; 220: 172-180.
129. Schurch S, Bachofen H, Goerke J, Possmayer F. A captive bubble method reproduces the in situ behaviour of lung surfactant monolayers. J Appl Physiol 1989; 67: 2389-2396.
130. Honda Y, Kuroki Y, Shijubo N et al. Aberrant appearance of surfactant protein A in sera of patients with idiopathic pulmonary fibrosis and its clinical significance. Respiration 1995; 62: 64-69.
131. Kollef MH, Schuster DP. The acute respiratory distress syndrome. N Engl J Med 1995; 332: 27-37.
132. Liau DF, Barrett CR, Bell ALL, Ryan SF. Functional abnormalities of lung surfactant in experimental acute alveolar injury in the dog. Am Rev Respir Dis 1987; 136: 395-401.
133. Tahvanainen J, Hallman M. Surfactant abnormality after endotoxin-induced lung injury in guinea pigs. Eur J Respir Dis 1987; 71: 250-258.
134. Lewis JF, Veldhuizen R, Possmayer F et al. Altered alveolar surfactant is an early marker of acute lung injury in septic adult sheep. Am J Respir Crit Care Med 1994; 150: 123-130.
135. Eijking EP, Gommers D, So KL, Vergeer M, Lachmann B. Surfactant treatment of respiratory failure induced by hydrochloric acid aspiration in rats. Anesthesiology 1993; 78: 1145-1151.
136. Baughman RP, Stein E, MacGee J, Rashkin M, Sahebjami H. Changes in fatty acids in phospholipids of the bronchoalveolar fluid in bacterial pneumonia and in adult respiratory distress syndrome. Clin Chem 1984; 30: 521-523.
137. Pison U, Obertacke U, Brand M et al. Altered pulmonary surfactant in uncomplicated and septicemia-complicated courses of acute respiratory failure. J Trauma 1990; 30: 19-26.
138. Gregory TJ, Longmore WJ, Moxley MA et al. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991; 88: 1976-1981.
139. Seeger W, Günther A, Walmrath HD, Grimminger F, Lasch HG. Alveolar surfactant and adult respiratory distress syndrome - pathogenetic role and therapeutic prospects. Clin Investig 1993; 71: 177-190.
140. Lewis JF, Jobe AH. Surfactant and the adult respiratory distress syndrome. Am Rev Respir Dis 1993; 147:218-233.
141. Seeger W, Günther A. Surfactant and adult respiratory distress syndrome. In: Müller B, von Wichert P, eds. Lung Surfactant: Basic Research in the Pathogenesis of Lung Disorders. Basel: Karger, 1994, pp. 222-231.
142. Kobayashi T, Nitta K, Ganzuka M, Inui S, Grossmann G, Robertson B. Inactivation of exogenous surfactant by pulmonary edema fluid. Pediatr Res 1991; 29: 353-356.
143. Holm BA, Matalon S. Role of pulmonary surfactant in the development and treatment of adult respiratory distress syndrome. Anesth Analg 1989; 69: 805-818.
144. Fuchimukai T, Fujiwara T, Takahashi A, Enhorning G. Artificial pulmonary surfactant inhibited by proteins. J Appl Physiol 1987; 62: 429-437.
145. Seeger W, Stohr G, Wolf HRD, Neuhof H. Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J Appl Physiol 1985; 58: 326-338.
146. Holm BA, Notter RH, Finkelstein JN. Surface property changes from interactions of albumin with natural surfactant and extracted lung lipids. Chem Phys Lipids 1985; 38: 287-298.
147. Holm BA, Notter RH. Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activity. J Appl Physiol 1987; 63: 1434-1442.
148. Seeger W, Elssner A, Günther A, Krämer HJ, Kalinowski HO. Lung surfactant phospholipids associate with polymerizing fibrin: loss of surface activity. Am J Respir Cell Mol Biol 1993; 9: 213-220.
149. Idegami K, Mori K, Misumi A, Akagi M. Changes of alveolar stability and phospholipids in pulmonary surfactant in acute pancreatitis. Jap J Surgery 1983; 13: 227-235.
150. 2. Am Rev Respir Dis 1991; 143: 1102-1109.
151. Holm BA, Keicher L, Liu M, Sokolowski J, Enhorning G. Inhibition of pulmonary surfactant function by phospholipases. J Appl Physiol 1991; 71: 317-321.
152. Holm BA. Surfactant inactivation in adult respiratory distress syndrome. In: Robertson B, van Golde LMG, Batenburg JJ, eds. Pulmonary Surfactant. From Molecular Biology to Clinical Practice. Amsterdam: Elsevier, 1992, pp. 665-684.
153. Froese AB. Exogenous surfactant therapy in ARDS - lessons from the neonatal ICU. Chest 1994; 105: 1310-1312.
154. Lachmann B, van Daal GJ. Adult respiratory distress syndrome: Animal models. In: Robertson B, van Golde LMG, Batenburg JJ, eds. Pulmonary Surfactant. From Molecular Biology to Clinical Practice. Amsterdam: Elsevier, 1992, pp. 635-663.
155. Nosaka S, Sakai T, Yonekura M, Yoshikawa K. Surfactant for adults with respiratory failure. Lancet 1990; 336: 947-948.
156. Lachmann B. Animal models and clinical pilot studies of surfactant replacement in adult respiratory distress syndrome. Eur Respir J 1989; 2 (suppl. 3): 98s-103s.
157. Richman PS, Spragg RG, Robertson B, Merritt TA, Curstedt T. The adult respiratory distress syndrome: first trials with surfactant replacement. Eur Respir J 1989; 2 (suppl. 3): 109s-111s.
158. Heikinheimo M, Hynynen M, Rautiainen P, Andersson S, Hallman M. Kukkonen S. Successful treatment of ARDS with two doses of synthetic surfactant. Chest 1994; 105: 1263-1264.
159. Spragg RG, Gilliard N, Richman P et al. Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome. Chest 1994; 105: 195-202.
160. Weg JG, Balk RA, Tharatt RS et al. Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult resiratory distress syndrome. JAMA 1994; 272: 1433-1438.
161. Lachmann B, Gommer D. Is it rational to treat pneumonia with exogenous surfactant? Eur Respir J 1993; 6: 1427-1428.
162. Hoffman AGD, Lawrence MG, Ognibene FP et al. Reduction of pulmonary surfactant in patients with human immunodeficiency virus infection and Pneumocystis carinii pneumonia. Chest 1992; 102: 1730-1736.
163. Escamilla R, Prcvost MC, Hcrmant C, Caratcro A, Cariven C, Krempf M. Surfactant analysis during pneumocystis carinii pneumonia in HIV-infected patients. Chest 1992; 101: 1558-1562.
164. Escamilla R, Prevost MC, Cariven C, Hermant C, Krempf M, Chap H. Bronchoalveolar lavage phospholipid abnormalities in HIV-infected patients. Eur Respir J 1993; 6: 1301-1307.
165. O'Riordan DM, Standing JE, Kwon KY, Chang D, Crouch EC, Limper AH. Surfactant protein D interacts with pneumocystis carinii and mediates organism adherence to alveolar macrophages. J Clin Invest 1995; 95: 2699-2710.
166. van Daal G-J, Bos JAH, Eijking EP, Gommers D, Hannappel E, Lachmann B. Surfactant replacement therapy improves pulmonary mechanincs in end-stage influenza A pneumonia in mice. Am Rev Respir Dis 1992; 145: 859-863.
167. Mikawa K, Maekawa N, Nishina K, Takao Y, Yaku H, Obara H. Selective intrabronchial instillation of surfactant in a patient with pneumonia: a preliminary report. Eur Respir J 1993; 6: 1563-1566.
168. Baughman RP, Strohofer S, Dohn M. Decreased phosphatidycholine in the lung fluid of patients with sarcoidosis. Lipids 1985; 20: 496-499.
169. Müller-Quernheim J, Pfeifer S, Männel D, Strausz J, Ferlinz R. Lung-restricted activation of the alveolar macrophage/monocyte system in pulmonary sarcoidosis. Am Rev Respir Dis 1992; 145: 187-192.
170. Guzman J, Wang YM, Kalycioglu O et al. Increased surfactant protein A content in human alveolar macrophages in hypersensitivity pneumonitis. Acta Cytol 1992; 36: 668-673.
171. Richman PS, Batcher S, Catanzaro A. Pulmonary surfactant supresses the immmune lung injury response to inhaled antigen in guinea pigs. J Lab Clin Med 1990; 116: 18-26.
172. Rich EA. Pulmonary surfactant as a physiologic immunsuppressive agent. J Lab Clin Med 1990; 116: 4-5.
173. Kawanami O, Ferrans VJ, Crystal RG. Structure of alveolar epithelial cells in patients with fibrotic lung disorders. Lab Invest 1982; 46: 39-53.
174. Hook GER, Gilmore LB, Talley FA. Dissolution and reassembly of tubular myelin-like multilamellated structures from the lungs of patients with pulmonary alveolar proteinosis. Lab Invest 1986; 55: 194-208.
175. Honda Y, Takahashi H, Shijubo N, Kuroki Y, Akino T. Surfactant protein-A concentration in bronchalveolar lavage fluids of patients with pulmonary alveolar proteinosis. Chest 1993; 103: 496-499.
176. Masuda T, Shimura S, Sasaki H, Takishima T. Surfactant aproprotein-A concentration in sputum for diagnosis of pulmonary alveolar proteinosis. Lancet 1991; 337: 580-582.
177. deMello DE, Heyman S, Phelphs DS et al. Ultrastructure of lung in surfactant protein B deficiency. Am J Respir Cell Mol Biol 1994; 11: 230-239.
178. Vorbroker DK, Profitt SA, Nogeee LM, Whitsett JA. Aberrant processing of surfactant protein C in hereditary SP-B defiency. Am J Physiol 1995; 268: L647-L656.
179. Klepetko W, Lohninger A, Wisser W et al. Pulmonary surfactant in bronchoalveolar lavage after canine lung transplantation: effect of L-carnitine application. J Thorac Cardiovasc Surg 1990; 99: 1048-1058.
180. Veldhuizen RA, Lee J, Sandler D et al. Alterations in pulmonary surfactant composition and activity after experimental lung transplantation. Am Rev Respir Dis 1993; 148: 208-215.
181. Novick RJ, Veldhuizen RAW, Possmayer F, Lee J, Sandier D, Lewis JF. Exogenous surfactant therapy in thirty-eight hour lung graft preservation for transplantation. J Thorac Cardiovasc Surg 1994; 108: 259-268.
182. Erasmus ME, Peterson AH, Oetomo SB, Prop J. The function of surfactant is impaired during the reimplantation response in rat lung transplants. J Heart Lung Transplant 1994; 13: 791-802.
183. Hamm H, Tschorn H, Hohlfeld J et al. Surfactant protein A (SP-A) levels are decreased in bronchoalveolar lavage (BAL) of lung transplant (LTX) patients. Am J Respir Crit Care Med 1995; 151: A92.
184. Otis DR, Johnson M, Pedley TJ, Kamm RD. Role of pulmonary surfactant in airway closure: a computational study. J Appl Physiol 1993; 75: 1323-1333.
185. Enhorning G, Holm BA. Disruption of pulmonary surfactant's ability to maintain openness of a narrow tube. J Appl Physiol 1993; 74: 2922-2927.
186. McFadden ERJ, Gilbert IA. Asthma. N Engl J Med 1992; 327: 1928-1937.
187. Lachmann B, Becher G. Protective effect of lung surfactant on allergic bronchial constriction in guinea pigs. Am Rev Respir Dis 1986; 133 (suppl): A118.
188. Kurashima K, Ogawa H, Ohka T, Fujimura M, Matsuda T, Kobayashi T. A pilot study of surfactant inhalation for the treatment of asthmatic attack. Jpn J Allergol 1991; 40: 160-163.
189. Hohlfeld J, Molthan J, Hoymann HG, Fabel H, Heinrich U. Aerosolized surfactant inhibits acetylcholine-induced bronchoconstriction in rats in vivo. Am J Respir Crit Care Med 1994; 149: A97.
190. Hohlfeld J, Molthan J, Hoymann HG, Fabel H, Heinrich U. Bronchoconstriction induced by aerosolized acetylcholine but not by acetylcholine given intravenously is inhibited by aerosolized surfactant in rats. Eur Respir J 1994; 7: 47s.
191. Finkelstein JN. Physiologic and toxicologic responses of alveolar type II cells. Toxicology 1990; 60: 41-52.
192. Cooper JA, White DA, Matthay RA. Drug-induced pulmonary disease. Part 1: Cytotoxic drugs. Am Rev Respir Dis 1986; 133: 321-340.
193. Cooper JA, White DA, Matthay RA. Drug-induced pulmonary disease. Part 2: Noncytotoxic drugs. Am Rev Respir Dis 1986; 133: 488-505.
194. Thrall RS, Swendsen CL, Shannon TH et al. Correlation of changes in pulmonary surfactant phospholipids with compliance in bleomycin-induced
195. Horiuchi T, Mason RJ, Kuroki Y, Cherniack RM. Surace and tissue forces, surfactant protein A, and the phospholipid components of pulmonary surfactant in bleomycin-induced pulmonary fibrosis in the rat. Am Rev Respir Dis 1990; 141: 1006-1013.
196. Osanai K, Takahashi K, Sato S et al. Changes of lung surfactant and pressure-volume curve in bleomycin-induced pulmonary fibrosis. J Apply Physiol 1991; 70: 1300-1308.
197. Joshi UM, Kodavanti RS, Coudert B, Dwyer TM, Mehendale HM. Types of interaction of amphiphilic drugs with phospholipid vesicles. J Pharmacol Exp Ther 1988; 246: 150-157.
198. Kodavanti UP, Mehendale HM. Amiodarone- andf desethylamiodarone-induced pulmonary phospholipidosodis, inhibition of phospholipase in vivo, and alteration of [14C]amiodarone uptake by perfused lung. Am J Respir Cell Mol Biol 1991; 4: 369-378.
199. Padmavathy B, Devaraj H, Devaraj N. Amiodarone-induced changes in surfactant phospholipids of rat lung. Nauny-Schmiedebergs Arch Pharmacol 1993; 347: 421-424.
200. Enhorning G. Surfactant replacement in adult respiratory distress syndrome. Am Rev Respir Dis 1989; 140: 281-283.
201. Merritt TA, Strayer DS, Hallman M. Spragg RD, Wozniak P. Immunologic consequences of exogenous surfactant administration. Seminars in Perinatology 1988; 12: 221-230.
202. Strayer DS, Merritt TA, Hallman M. Surfactant replacement: immunological considerations. Eur Respir J 1989; 2 (Suppl 3): 91s-96s.
203. Strayer DS, Merritt TA, Hallman M. Levels of SP-A-anti-SP-A immune complexes in neonatal respiratory distress syndrome correlate with subsequent development of bronchopulmonary dysplasia. Act Paed 1995; 84: 128-131.
204. Chida S, Phelps DS, Soil RF, Taeusch HW. Surfactant proteins and anti-surfactant antibodies in sera from infants with respiratory distress syndrome with and without surfactant treatment. Pediatrics 1991; 88: 84-89.